Clinical trial · Interventional
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant
NCT01007292CI-TRIAL-00019523completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate response rate, survival, safety and tolerability of YM155 given in combination with rituximab in subjects with Non-Hodgkin's Lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Rituximab | Biological | Rituximab | ALIAS |
| YM155 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- YM155 plus rituximab
- interventionNames
- Drug: YM155
- Biological: Rituximab
Primary outcomes (1)
- measure
- Objective response rate (Confirmed Complete Remission +Confirmed Partial Remission)
- timeFrame
- After the last non-progressing subject receives 8 cycles of treatment or discontinues the treatment
Secondary outcomes (8)
- measure
- Confirmed Complete remission rate
- timeFrame
- After the last non-progressing subject receives 8 cycles of treatment or discontinues the treatment
- measure
- Confirmed Partial remission rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Any stage, histologically confirmed CD20-positive primary or transformed diffuse large B cell lymphoma (DLBCL)or grade 3 follicular lymphoma (FL) * Ineligible for or have previously received an autologous stem cell transplant (ASCT) * Relapsed following receipt of the last dose of systemic chemotherapy or ASCT * At least one prior chemotherapy regimen. Prior chemotherapy regimen must have contained anthracycline (unless contraindicated) * If the subject is female, she must be non-pregnant and non-lactating at the Baseline Visit. All sexually active males and females of childbearing potential must agree to use an adequate method of contraception throughout the study period * Eastern Cooperative Oncology Group (ECOG) performance status \</= 1 Exclusion Criteria: * Use of any standard/experimental anti-lymphoma drug therapy within 21 days of the Baseline Visit * Use of systemic steroids within 5 days of the Baseline Visit (except for the purposes of pre-medication prior to study regimen treatment) * Prior allogeneic stem cell transplant (SCT) * The subject has been previously treated with YM155 * The subject has known human immunodeficiency virus (HIV), hepatitis B surface antigen, or hepatitis C antibody * The subject has received other investigational therapy or procedures within 21 days prior to the first study drug administration
References
Publications (0)
Data not yet available
No reference posted for this study.